[Brief Introduction of Seminar]

Agricultural by-products of Capsicum annuum, including leaves and stems, are largely discarded despite being rich sources of bioactive compounds such as polyphenols and flavonoids. This study aims to investigate the potential of pepper by-product extracts as novel agents for improving blood circulation and preventing cardiovascular diseases.

The research focuses on elucidating the mechanisms by which these extracts regulate platelet activation, thrombus formation, endothelial function, oxidative stress, and inflammatory responses. Furthermore, their applicability as functional food ingredients and natural therapeutics for vascular health will be evaluated. The study is expected to provide scientific evidence for the valorization of agricultural waste and the development of high-value natural products for cardiovascular health promotion.

[Brief Introduction of Speaker]

I am a Principal Researcher at the Korea Institute of Oriental Medicine (KIOM). His research focuses on platelet biology, thrombosis, vascular inflammation, and the development of natural products for cardiovascular health. He has conducted extensive studies on the discovery of bioactive natural compounds and the elucidation of their pharmacological mechanisms in blood circulation improvement and cardiovascular disease prevention.

Recently, his research has expanded to AI-assisted natural product discovery, organoid-based disease models, and human-mimetic systems for translational biomedical research. He is actively involved in the development of functional foods and natural-product-based therapeutics.​  

[Brief Introduction of Seminar]

Efficacy Evaluation and Preliminary Clinical Study for the Development of a Health Functional Food Based on Standardized Black Ginseng Extract for Bronchial Health Improvement

[Brief Introduction of Speaker]

The research interests of Dr. Ryu are on the isolation, characterization and biological evaluation of natural products of higher plant origin, and he has worked in particular on compounds with potential chronic inflammatory diseases and metabolic diseases, in addition to the scientific study of botanical dietary supplements.​  

[Brief Introduction of Seminar]

▷ This technology converts Schisandra pomace, an agricultural by-product, into a high-value functional material through a solid-state fermentation process, and develops an extract containing bioactive compounds that may help improve sleep quality.

▷ Based on the functional evaluation, standardization, and formulation technology of solid-state fermented Schisandra pomace extract, this technology presents its potential commercialization as a health functional food ingredient and sleep-care product.

[Brief Introduction of Speaker]

(Career History)

• 1996.03.02. ~ 2000.08.26. B.S. in Chemistry, Pusan National University

• 2001.03.02. ~ 2007.02.14. Ph.D. in Chemistry, Pohang University of Science and Technology (POSTECH)

Major: Bioinorganic Materials Chemistry

• 2007.01.16. ~ 2008.04.30. Postdoctoral Researcher, Pohang University of Science and Technology (POSTECH)

• 2008.05.01. ~ 2010.06.30. Postdoctoral Researcher, Max Planck Institute, Germany

• 2010.04.19. ~ 2012.09.30. Senior Researcher, Nanogea, Inc., USA

• 2015.11.01. ~ 2019.10.31. Visiting Professor, School of Chemical Engineering and Polymer Engineering, Sungkyunkwan University

• 2024.03.01. ~ 2025.12.31. Adjunct Professor, Department of Chemical Engineering, Kyungsung University

(Awards and Honors)

• Prime Minister’s Commendation, 2025

• Academic Award, Korean Adhesion and Interface Society, 2024

• Minister’s Commendation, Ministry of Trade, Industry and Energy, 2021

• Chairperson’s Award, National Research Council of Science & Technology, 2021

• KRICT Achievement Award, 2021 and 2025

(Major Research Areas and Expertise)

• Research and development in precision chemical materials and functional materials

• Development and application of interface and surface control materials

• Research, development, and application of industrially applicable materials

• Development of natural product-based and bio-based functional materials

• Expertise in technology transfer, patent acquisition, and industrialization of • R&D outcomes

Experience in planning and conducting national R&D projects based on industry–academia–research collaboration​  

[Brief Introduction of Seminar]

Development of Health Functional Foods for Sleep Improvement Using Glehnia littoralis Extract

[Brief Introduction of Speaker]

1. Head, Functional Platform Research Group, Korea Food Research Institute

2. Professor, Food Biotechnology, UST​  

[Brief Introduction of Seminar]

Against the backdrop of recent health and wellness trends, the Japanese health food market continues to evolve constantly. This development is driven by the diversification of products addressing a wide range of demands from seniors to younger generations, as well as the solid establishment of the "Foods with Function Claims" system, which allows products to display specific health benefits.

[Brief Introduction of Speaker]

After graduating from university, they began their career in 1998 at a major Japanese food manufacturer before joining Yano Research Institute in 2003. They specialize in the overall food market, with a particular focus on the health food and processed food industries. Currently serving as the leader of the Food Group, they oversee the department's entire domain.

They have an extensive track record in feasibility studies for new business ventures, market entry research for foreign companies entering Japan, industry development support for local governments, and market expansion assistance for foreign embassies in Japan.​ 

[Brief Introduction of Speaker]

CEO of CAREGEN (2001~) - Post Doc. Northwestern University, Hormonal & Dietary gene modulation in Breast cancer cells (2001) 

Ph.D. Animal Science, Cornell University, BRCA Research in Bovine mammary gland (2000) 

M.S. Biochemistry, University of Texas at San Antonio (1996) 

B.S. Genetic Engineering, SungGyunGwan University, Korea (1994)​  

[Brief Introduction of Seminar]

Lipid excipients have a proven history of enhancing bioavailability of drugs through the improvement of solubility, permeability, and absorption. Being often liquid at room temperature, they are mainly formulated in liquid forms. That said, oral solid dosage forms such as tablets could benefit from the advantages of lipid excipients. This presentation will highlight different processes to incorporate lipid excipients in oral tablets or powders.

Key topics will include:

- Benefits of lipid excipients for bio-enhancement

- Market references

- Case studies highlighting formulation strategies and associated manufacturing processes.

[Brief Introduction of Speaker]

Hongyi holds a Bachelor’s degree in Pharmacy (1st class) and PhD in Pharmaceutical Technology from the National University of Singapore (NUS). During his research, he investigated on solid oral dosage formulations at GEA-NUS laboratory under the supervision of A/Prof Chan Lai Wah and A/Prof Paul Heng.

Prior to joining Gattefossé, Hongyi was a senior technical engineer at Merck Sharpe and Dohme (MSD) and formulation scientist at Clinuvel Pharmaceuticals.

At Gattefossé since 2022, Hongyi is responsible for technical marketing in the pharmaceutical division for the Asia Pacific region, covering oral, topical and rectal drug delivery. Additionally, he is responsible for sales in Thailand, Malaysia, Australia and New Zealand. Outside of work, Hongyi is a keen volleyball player and enjoys travelling.​  

[Brief Introduction of Seminar]

Vascular health is no longer limited to improving blood circulation. Increasingly, effective vascular care requires addressing both vascular occlusion caused by blood clots and vascular stiffness resulting from arterial calcification.

This seminar will explore these two key aspects of vascular health—"Blocked Blood Vessels" and "Hardened Blood Vessels"—by reviewing the mechanisms of action and the latest scientific research on Nattokinase and Vitamin K2. We will also introduce an innovative solution for vascular and bone health by combining these two functional ingredients.

In addition, GF Fermentech will present its proprietary fermentation technology and high-quality vegan ingredients, highlighting their superior stability and quality competitiveness. The seminar will also discuss practical strategies for applying these ingredients to the development of differentiated health functional food products and creating added value in the marketplace.

[Brief Introduction of Speaker]

Mr. Bok-Jun Park, Team Leader of the Sales & Marketing Team at GF Fermentech, holds a Master's degree in Biotechnology and has over 20 years of experience in the food, nutraceutical, and cosmetic ingredient industries. Throughout his career, he has specialized in the research, technical sales, and marketing of functional ingredients.

He has worked extensively with a wide range of microbial fermentation-based functional ingredients, including amino acids, yeast, DHA, chlorella, astaxanthin, and GABA. His experience spans technical support, B2B sales and marketing, and assisting customers throughout the entire product development process—from ingredient selection and product planning to market application.

Currently, at GF Fermentech, Mr. Park is responsible for the B2B sales and marketing of fermentation-based functional ingredients, with a particular focus on Vitamin K2 and Nattokinase. Leveraging scientific evidence and extensive industry expertise, he provides differentiated ingredient solutions for vascular and bone health.​  

[Brief Introduction of Seminar] 

A National Treasure "Antrodia cinnamomea" in Taiwan: Revolutionary Technology to Cultivate its Mycelium & R&D for Hepatoprotection and Immunomodulation

Taiwan's legendary 'Forest Ruby' - from traditional remedy to global clinical evidence

Antrodia cinnamomea (niu-chang-chih) is a rare medicinal fungus endemic to Taiwan, growing exclusively on the heartwood of the endangered Cinnamomum kanehirae tree. Known as the "Forest Ruby" for its brilliant red fruiting body, it has been revered in traditional medicine for centuries for hepatoprotection, anti-inflammation, detoxification, hangover relief, and immune enhancement. Wild harvesting has led to near-extinction of natural resources, and the tree species is now legally protected. Antromax® overcomes this supply challenge through solid-state cultivation while delivering superior active compound profiles compared to wild material, enabling standardized, scalable, and sustainable production for global commercial application.

PATENTED FERMENTATION TECHNOLOGY

Greenyn's proprietary adversity-domestication fermentation platform is the technological breakthrough. Unlike conventional liquid fermentation (minimal triterpenoids) or log-cultivation (2-3 years, unsustainable), this platform simulates the fungus's native habitat stress conditions - controlled temperature, humidity, pH, and nutritional stress - triggering robust secondary metabolite production.

Key Metrics: Total triterpenoids exceed 180% of 3-year-old wild fruiting bodies.

Cultivation Cycle: 3-4 months vs. 2-3 years wild.

8-Country Patent Family: Taiwan (1543706), USA (US9458421B2), Germany, Japan (5814322/3188254), China (ZL201310432728.7), Malaysia (MY167124A), Korea (10-2125300), and Belgium.

STRONG CLINICAL EVIDENCE & FUNCTIONAL BENEFITS

Hepatoprotection (RCT, Japan): Double-blind, placebo-controlled 12-week trial in 38 sub-healthy adults (ALT 30-51 IU/L) demonstrated significant ALT/AST reduction.

Chronic Hepatitis B (RCT, China Medical University Hospital): Adjuvant therapy to Entecavir showed enhanced viral suppression and liver enzyme normalization.

Alcohol Metabolism: Animal studies showed ADH +40%, ALDH +42%, accelerating sobriety by 7 hours.

Safety Profile: Passed acute toxicity (NOAEL), 90-day sub-chronic, genotoxicity testing (Ames negative), and teratogenicity testing.

Global Compliance & Certifications: USFDA NDI No. 1170 (world's first), health food certification, SNQ National Quality Mark, ISO 22000, FSSC 22000, GMP, and Halal.

​[Brief Introduction of Speaker] 

Dr. Leon Hsu

CEO & R&D Director, Greenyn Biotechnology (TPEx: 6846)

EDUCATION

Ph.D. in Food Science and Biotechnology, National Chung Hsing University, Taiwan

Cross-disciplinary training in molecular biology, food chemistry, and nutraceutical product development  

EXPERIENCE

CEO & R&D Director, Greenyn Biotechnology (Listed on TPEx: 6846) - leading 150+ professionals

Transitioned Greenyn from ingredient distributor into a science-driven, publicly listed global innovator exporting to 15+ countries

Full-spectrum R&D pipeline: functional peptide engineering, solid-state fermentation, clinical trials, international regulatory submissions (FDA, EFSA, Japan, Korea, China)

KEY ACHIEVEMENTS

Invented 10+ proprietary branded ingredients including Insumate (patented bitter melon peptide for blood sugar management), Antromax (world's first FDA NDI Antrodia cinnamomea), Citrusvel and more across metabolic health, hepatoprotection, immunity, and immune health etc.

100+ international patents across 8 countries (US, EU, JP, CN, KR, MY, TW, DE) for functional ingredient compositions, fermentation technologies, and peptide sequences

Published 10+ peer-reviewed international journal papers on functional peptide discovery, clinical validation, and bioactive compound characterization

Awarded 30+ international invention prizes, and National Innovation Award and multiple domestic invention honors

Achieved 2 USFDA-NDI, Received 2 SNQ National Quality Marks, multiple health food functional claims (liver function and immune health), and spearheaded Greenyn's IPO (TPEx: 6846)